Previous Close | 164.61 |
Open | 164.55 |
Bid | 0.00 x 900 |
Ask | 163.60 x 800 |
Day's Range | 163.10 - 164.85 |
52 Week Range | 155.72 - 186.69 |
Volume | |
Avg. Volume | 7,080,273 |
Market Cap | 427.101B |
Beta (5Y Monthly) | 0.56 |
PE Ratio (TTM) | 28.86 |
EPS (TTM) | 5.66 |
Earnings Date | Apr 17, 2023 - Apr 21, 2023 |
Forward Dividend & Yield | 4.52 (2.62%) |
Ex-Dividend Date | Nov 21, 2022 |
1y Target Est | 183.80 |
Today is Tuesday, February 7th, and this is your FT News Briefing. Johnson & Johnson can no longer sidestep certain liability lawsuits. Google is playing catch-up with its artificial intelligence technology.
Janssen, a unit of Johnson & Johnson (NYSE: JNJ), announced topline results from the proof-of-concept Phase 2 open-label UNITY trial for pregnant adults at high risk for severe hemolytic disease of the fetus and newborn. In 2020, Johnson & Johnson shelled out $6.5 billion to acquire Momenta Pharmaceuticals Inc, gaining access to its lead product, nipocalimab. HDFN is a rare condition that can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.